Europe Sun
EuropeSun.com Friday 12th March 2010 Edition 2010/1006
  • More Europe Markets News

  • Fire breaks out in London building
  • US unconvinced over Pak Army's U-turn against Taliban commanders: Expert
  • Meteorites could have kick-started life on earth 4 billion years ago
  • Archaeologists to embark on investigation into Shakespeare's later life
  • Walmart under fire for cutting price of black Barbies to nearly half of white ones
  • Henman prefers golf instead of captaining Britain's Davis Cup team
  • Cambridge to train police chiefs in India
  • 'The Wizard of Oz' to get 3D treatment?
  • Car that uses 10,000 cups of espresso as fuel!
  • McDonald's offers qualification in work experience!
  • Cheryl Cole may take back Ashley, says body language expert
  • '24 beers a day' Brit losing teeth at 22
    Get Europe Markets News headlines emailed to you daily.

    Popular anti-depressant interferes with breast cancer treatment
    Europe Sun
    Tuesday 9th February, 2010  
    (ANI)


    London, Feb 9 : Taking a popular anti-depressant could slash chances of survival for women battling breast cancer, says a new study.

    Seroxat can interfere with a key breast cancer drug, say experts.

    Women taking tamoxifen to fight breast tumours were less likely to survive if they also took the antidepressant, reports The Daily Express.

    The researchers said the results had "major implications for clinical practice" and warned women on Seroxat to see their GP.

    In the British Medical Journal study, researchers from the University of Toronto looked at 2,430 women aged over 66 who were taking tamoxifen and one of five anti-depressants. Those taking Seroxat were more likely to die from breast cancer and were slightly more likely to die from any other cause compared with women not on Seroxat.

    The authors said: "Our findings indicate that the choice of anti
    ­depressant can significantly affect survival in women receiving tamoxifen for breast cancer."

      Email this story to a friend

    Have your say on this story

    Your nickname (optional)
    Message